Skip to main content

SIGNIFICANT IMPROVEMENT IN BOTH ITCH RELIEF
AND NODULE CLEARANCE

PRIME 18+ YEARS

PROPORTION OF PATIENTS WITH ≥4-POINT
IMPROVEMENT IN
WI-NRS + IGA PN-S

0 OR 1 AT WEEK 24

(secondary endpoint)1-3
  • A nominal difference was observed at Week 8 (12% with DUPIXENT vs 0% with placebo) and at Week 12 (20% with DUPIXENT vs 5% with placebo)3
    PRIME2 18+ YEARS
  • At Week 8 and Week 12, 8% and 17% of patients treated with DUPIXENT vs 5% and 9% with placebo, respectively, had both improvement in itch and nodule clearance. A significantly greater proportion of DUPIXENT patients achieved both improvement in itch and nodule clearance at Week 24 (32% with DUPIXENT vs 9% with placebo; P<0.001)1-3

Definitive conclusions cannot be made for results earlier than at 24 weeks in PRIME and PRIME2. Data were not multiplicity controlled.

IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; WI-NRS, Worst Itch numerical rating scale.

Explore itch results

VIEW WI-NRS RESULTS